Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and Vertex Pharmaceuticals (VRTX)

Tipranks - Tipranks - Thu Apr 16, 8:54AM CDT

Analysts fell to the sidelines weighing in on Johnson & Johnson (JNJ) and Vertex Pharmaceuticals (VRTX) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Claim 30% Off TipRanks

Johnson & Johnson (JNJ)

Bank of America Securities analyst Jason Gerberry maintained a Hold rating on Johnson & Johnson today and set a price target of $254.00. The company’s shares closed last Wednesday at $237.98.

According to TipRanks.com, Gerberry is a 5-star analyst with an average return of 18.4% and a 61.1% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Mineralys Therapeutics, Inc., and Amylyx Pharmaceuticals Inc. ;'>

Johnson & Johnson has an analyst consensus of Moderate Buy, with a price target consensus of $262.33, which is a 9.3% upside from current levels. In a report issued on April 2, J.P. Morgan also maintained a Hold rating on the stock with a $250.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Vertex Pharmaceuticals (VRTX)

In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Hold rating on Vertex Pharmaceuticals, with a price target of $441.00. The company’s shares closed last Wednesday at $445.93.

According to TipRanks.com, Ijem is a 5-star analyst with an average return of 22.8% and a 48.2% success rate. Ijem covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, and Rhythm Pharmaceuticals. ;'>

Currently, the analyst consensus on Vertex Pharmaceuticals is a Strong Buy with an average price target of $559.61, representing a 26.0% upside. In a report issued on March 31, TipRanks – Anthropic also downgraded the stock to Hold with a $472.00 price target.

Read More on JNJ:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).